Introduction
Bladder cancer represents the 11th most common malignancy worldwide, and the 7th most common in men [1] . Smoking is the most established risk factor for bladder cancer, while other risk factors include occupational exposure to aromatic amines and hydrocarbons. The vast majority of bladder cancers are of urothelial histology, and localized urothelial carcinoma of the bladder (UCB) is broadly categorized into non-muscle-invasive bladder cancer (NMIBC) and muscleinvasive disease. Approximately 75% of bladder tumours present as NMIBC and this disease entity is the focus of the present review [2] .
There is considerable debate regarding the management of this complicated disease process, which exhibits a variable clinical course, punctuated by risk of recurrence and progression to invasive disease. Adherence to guidelines is reportedly low; reasons for this are speculative, but perhaps confusion about the different guidelines plays a role in poor adoption of fundamental aspects of NMIBC management [3] [4] [5] . We sought to summarize the findings of four major organizational guidelines, with an emphasis on both differences and areas of unanimity.
Methods
We performed a MEDLINE/PubMed search, from 2010 to the present, of guidelines on NMIBC and manually searched the websites of urological or oncological societies and journals to identify relevant guidelines. The American Urological Association(AUA), Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), International Consultation on Urological Diseases, International Bladder Cancer Network, International Bladder Cancer Group, Canadian Urological Association and European Society for Medical Oncology guidelines were reviewed. We narrowed our review of guidelines to those that are most commonly used in practice, those most recently updated, and those with the most detail; namely, the AUA/SUO, EAU, NCCN and NICE guidelines. Each set of guidelines is based on systematic literature reviews by expert panels, but they differ in terms of topics addressed, detail and methodology.
AUA/SUO Guidelines
The AUA/SUO guidelines [6] panel consists of 13 members and 128 peer reviewers; evidence strength is graded as A, B or C and statements are provided as 'strong', 'moderate' or 'conditional recommendations', in addition to 'clinical principles' and 'expert opinion. ' The recently updated 2016 AUA/SUO guidelines adopt a risk-stratified approach in contrast to the 'index patient' approach that was employed in the 2007 iteration. The guidelines are available via PubMed search through the Journal of Urology and online via the AUA website: https://www.auane t.org/education/guidelines/non-muscle-invasive-bladder-cance r.cfm.
EAU Guidelines
The EAU guidelines [7] panel consists of 15 medical professionals and has continually updated NMIBC guidelines every 2-3 years since 2008, and most recently in 2016. Recommendations are classified according to their level of evidence (I-IV) and are given a grade of recommendation (A-D) according to a modification of the 2009 Oxford Centre for Evidence-Based Medicine Levels of Medicine [8] . The EAU guidelines are available via PubMed search through the journal European Urology and online via the EAU website: https://uroweb.org/guideline/non-muscle-invasive-bladder-ca ncer/.
NCCN Guidelines
The NCCN guidelines (USA) [9] include both NMIBC and muscle-invasive disease, and represents the work of 33 medical professionals, technical experts and patient advocates. The guidelines are based on a treatment algorithm and flow charts according to pathological stage and grade. Categories of evidence and consensus range from 1 (uniform consensus based on high-level evidence), 2A (uniform consensus based on lower-level evidence), 2B (consensus based on lower-level evidence) and 3 (major disagreement). Originally published in 1998, the NCCN guidelines on NMIBC are updated regularly with the most recent update in February 2016, and are available, free of cost, to registered users through the NCCN website: https://www.nccn.org/professionals/physician_gls/pdf/ bladder.pdf.
NICE Guidelines
The NICE guidelines (UK) [10] represent the work of 15 members including medical professionals, technical experts and patients meant to represent the lay public. Both NMIBC and muscle-invasive disease are combined into one document. Recommendations vary from 'must' (or 'must not'), representing a legal duty, and 'should' (or 'should not'), implying a strong recommendation, to 'consider', implying an option that is felt to do more good than harm and be cost-effective. The guidelines were most recently published in February 2015, will next be reviewed in 2019, and are available online: https://www.nice.org.uk/guidance/ ng2.
Results

Lifestyle Modification
Both the EAU and NICE guidelines recommend smoking cessation counselling based on studies suggesting active smoking increases risk of tumour recurrence and progression, and impairs response to immunotherapy [11, 12] .
Classification of Tumours
All guidelines statements adopt the 2009 American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system and define NMIBC as non-invasive papillary UCB (Ta), carcinoma in situ (CIS; Tis), or with invasion limited to the lamina propria (T1) [13, 14] .
While the grading system was just recently updated [15, 16] There is consensus on describing mandatory pathological features, including depth of invasion, presence of muscularis propria (detrusor muscle) in the specimen, presence of CIS, and variant histology.
Evaluation and Resection
Comprehensive history, physical examination, followed by cysto-urethroscopy, is required for initial evaluation of suspected bladder cancer, making note of macroscopic features (i.e. tumour size, site, number, configuration and any mucosal abnormalities).
Initial Transurethral Resection
Proper initial transurethral resection (TUR) of bladder tumour is a critical step in the initial management and staging of disease. Early recurrence and improper staging can result from inadequate resection of the initial tumour, inadequate sampling of muscularis propria or missing tumours such as CIS [20] [21] [22] .
There is consensus that all visible papillary tumours should be resected. The EAU offers specifics about TUR technique, including en bloc resection of small papillary tumours including the underlying bladder wall, while larger tumours should be resected in fractions and include the underlying detrusor muscle and edges of the resection area. Although the AUA and NCCN guidelines do not require sampling of the underlying detrusor muscle at initial TUR, this is recommended on re-TUR for T1 disease (AUA) or HG or T1 disease (NCCN).
Re-TUR
Repeating TUR in select cases is associated with discovering persistent tumour [22] [23] [24] , more accurate staging (especially if there is no detrusor muscle in the initial TUR) [20, 25] , improved recurrence-free survival [23] , and response to BCG [26] . All guidelines recommend re-TUR, for similar indications which should optimally be performed within 1-6 weeks ( Table 2) .
Evaluation of the Upper Tract
The AUA and NCCN recommend that all patients with confirmed NMIBC should have upper tract imaging performed. The EAU concludes that the need to perform routine upper tract imaging studies is questionable [27] , but does recommend upper tract imaging in select cases; tumours near the trigone, multiple tumours or high-risk tumours. NICE guidelines recommend upper tract evaluation only in new or recurrent high-risk NMIBC. It should be noted that many patients with newly diagnosed bladder cancer have had upper tract imaging as part of their haematuria evaluation.
Staging
The NCCN does not recommend routine chest, bone or brain imaging in the initial staging of NMIBC, but does recommend consideration of pelvic MRI for local staging of sessile or HG tumours. NICE recommends CT or MRI of the abdomen and pelvis if muscle-invasive disease is suspected or in patients being considered for radical treatment, and consideration of fluorodeoxyglucose positron emission tomography-CT when there are indeterminate findings. The EAU and AUA do not make staging recommendations.
Prostatic Urethral Sampling
The involvement of urothelial carcinoma at the prostatic urethra (PU) is a negative prognostic factor for recurrence and progression. The EAU recommends PU biopsy in cases of visible PU or bladder neck tumours, when bladder CIS is present/suspected, or in the case of positive cytology. The Table 2 Recommendations for performance of re-transurethral resection (if pursuing bladder-sparing approach). 
AUA
Random Bladder Biopsies
Some urothelial carcinomas, in particular CIS, may not be visible cystoscopically and may only be detected by random or 'mapping' biopsies [28] [29] [30] . Given the low yield in all-comers, no organization advocates random bladder biopsy routinely. Except for NICE, each organization suggests indications in which this strategy might be appropriate: AUA: positive cytology; EAU: CIS treated with intravesical BCG, positive cytology, exophytic tumour with a non-papillary appearance; and NCCN: sessile tumour or suspicion of HG/CIS. Additionally, the EAU suggests that photodynamic diagnosis (PDD)-guided biopsies may substitute for random biopsies, although strong evidence is lacking to support this approach.
Urine Cytology and Biomarkers
Urine cytology is the most widely accepted urinary biomarker, but is limited with respect to sensitivity and has issues related to inter-and intra-observer variability [31, 32] . The AUA makes no recommendation regarding urine cytology in the primary assessment but advocates its use in the surveillance of intermediate-and high-risk patients. Conversely, the EAU and NCCN guidelines recommend the use of urine cytology as an adjunct to cystoscopy at primary assessment and in the surveillance of high-risk tumours. NICE guidelines are the least specific, stating that it should be offered at the time of TURBT (or alternatively, enhanced cystoscopic visualization or other urinary biomarkers).
A number of commercially available urinary biomarkers (e.g. UroVysion, ImmuoCyt, NMP22, Bladder Tumour Antigen) for the detection of UCB are not routinely recommended because of inadequate performance characteristics [32] [33] [34] [35] . The AUA suggests that urinary biomarkers may be used to assess BCG response or 'adjudicate equivocal cytology' and the NCCN recommends consideration or urinary biomarkers in the surveillance setting, acknowledging unclear benefits.
Enhanced Cystoscopy
New technologies in the form of fluorescence cystoscopy (PDD) or narrow-band imaging focus on improving detection of small or flat lesions. Narrow-band imaging is less well studied, therefore, guidelines statements focus on PDD [36] . PDD does appear to improve detection, reduce residual disease after TUR, decrease recurrences and possibly decrease progression [37] [38] [39] . Both the AUA and NICE recommend enhanced cystoscopy be offered at the time of TUR. The EAU recommends PDD-guided biopsies in the setting of positive cytology but negative cystoscopy. The NCCN does not recommend routine use of PDD-enhanced cystoscopy, citing lack of evidence regarding reduced progression.
Risk Stratification
With the exception of the NCCN, guidelines classify NMIBC according to risk groupings based on combined pathological and clinical features reflecting likelihood of recurrence and progression (Table 3 ). These risk groupings provide the framework for surveillance protocols, adjuvant intravesical therapies, and guidance on when to continue or abandon conservative management and proceed with radical cystectomy (RC).
The EAU guidelines use the EORTC risk tables, based on the results of 2596 patients with TaT1 tumours who were randomized into seven trials for determining individual risks of recurrence and progression [19] . Importantly, these patients did not receive a re-TUR or maintenance BCG, limiting applicability. Recently, the EORTC published an updated model which included patients treated with 1-3 years of maintenance BCG, but excluded patients with CIS, and repeat TUR was not performed in high-risk patients [40] . The updated AUA guidelines adopt a similar system of risk grouping but incorporate prior intravesical BCG therapy on prognosis [41, 42] .
Variant Histologies
One controversial area in NMIBC is management of UCB with divergent differentiation (e.g. squamous or glandular) or variant histologies (e.g. micropapillary, nested, plasmacytoid, neuroendocrine, sarcomatoid). A number of studies report these to be adverse prognostic factors with limited response to intravesical BCG, thus advocating early RC; however, these studies are generally small cohorts and for some subtypes it is not clear that their prognosis or response to intravesical therapy truly differs from HG, high-stage UCB of the usual type [43] . Nonetheless, all guidelines consider variant histologies to be high-risk and advocate the consideration of aggressive management, including early RC.
Surveillance
Periodic cystoscopy is the mainstay of NMIBC management, as HG tumours have progression rates reported of 15-40%,
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© 2017 The Authors BJU International © 2017 BJU International and even LG tumours have a mean recurrence rate of 50% [43, 44] . Most guidelines recommend early initial cystoscopy and risk-stratified surveillance schedules (Table 4 ), with no high-level evidence to support a specific schedule. Uniquely, the NICE guidelines recommend that patients with low-risk NMIBC who are free from recurrence at 12 months may be discharged from routine urological follow-up. Additionally, all guidelines (except those of the NCCN, which make no comment) suggest that it is appropriate to consider officebased fulguration in lieu of TUR under anaesthesia for small solitary, papillary tumours in patients with an established history of LG Ta disease [45, 46] .
Intravesical Therapy
Immediate Intravesical Chemotherapy Instillation
Immediate instillation of intravesical chemotherapy after TUR has been shown to reduce recurrence in lower-risk NMIBC [47] [48] [49] [50] [51] . All guidelines recommend immediate Aggressive variant histology of urothelial carcinoma Any pTaG2 (grade no further specified) Any low-risk NMIBC recurring within 12 months CIS, carcinoma in situ; EAU, European Association of Urology; G, grade; HG, high grade; LG, low grade; LVI, lymphovascular invasion; NICE, National Institute for Health and Care Excellence; NMIBC, non-muscle-invasive bladder cancer; PUNLMP, papillary neoplasm of low malignant potential. Table 4 Surveillance recommendations for bladder recurrence in non-muscle-invasive bladder cancer.
AUA
All patients: initial cystoscopy within 3-4 months of completion of treatment Low-risk: cystoscopy 6-9 months later, and then annually for at least 5 years Intermediate-risk: cystoscopy + cytology every 3-6 months for 2 years, then every 6-12 months for years 3-4, and then annually thereafter High-risk: cystoscopy + cytology every 3-4 months for 2 years, then every 6 months for years 3-4, and then annually thereafter Upper tract evaluation: every 1-2 years in intermediate-or high-risk NMIBC, not routinely recommended for low-risk NMIBC EAU All patients: initial cystoscopy at 3 months Low-risk: another cystoscopy at 9 months later, then annually for 5 years. Consider stopping after 5 years without recurrence. Intermediate-risk: surveillance scheme between low and high risk High-risk: cystoscopy and cytology every 3 months for 2 years, then every 6 months until 5 years, and then annually thereafter Upper tract evaluation: yearly for high-risk NMIBC, no specific recommendations for low-or intermediate-risk NMIBC NCCN
LG Ta: cystoscopy at 3 months, and then at 'increasing intervals' (not specific about when safe to stop surveillance) HG Ta, T1, Tis: cystoscopy + cytology at every 3-6 months for first 2 years, and then at 'increasing intervals' thereafter Upper tract evaluation: every 1-2 years in HG NMIBC NICE All patients: cystoscopy at 3 months Low-risk: cystoscopy at 12 months, patients without recurrence may be discharged to PCP, do not offer routine cystoscpic follow-up after 12 months Intermediate-risk: cystoscopy at 9 and 18 months, then annually thereafter. Consider discharging to PCP after 5 years of disease free follow-up High-risk: cystoscopy every 3 months for 2 years, every 6 months for years 3-4, then annually thereafter. (Table 5) . Although considerable variation exists based, for example, on region, training and physician's patient volume, compliance with these recommendations is low [52, 53] . Among reasons for non-compliance with recommendations are concerns about side effects and logistical difficulty with immediate postoperative intravesical chemotherapy instillation. Additionally, with the exception of the NICE guidelines, recommendations for immediate intravesical chemotherapy instillation are based on presumed pathology, which is not a clearly defined criterion.
Induction and Maintenance Intravesical Therapy
The optimum dosing, schedule and indications for further intravesical treatment are not well-defined, but there is evidence that further adjuvant chemotherapy instillations are associated with a reduction in recurrence in patients with intermediate-risk disease [54, 55] . Additionally, several studies have confirmed the superiority of intravesical BCG over chemotherapy for prevention of NMIBC recurrence and progression [56] [57] [58] [59] [60] [61] [62] , and level 1 evidence supports the use of maintenance BCG therapy over induction alone [63] . These studies represent heterogeneous inclusion criteria, maintenance schedules and alternative treatments at recurrence; therefore, guidelines on this subject reflect disparate conclusions at lower strength recommendations ( Table 5 ).
The NICE guidelines are specific in recommending only an induction course of intravesical mitomycin C for intermediate-risk NMIBC with no mention of maintenance, while high-risk patients should be offered induction and maintenance BCG. The AUA recommends against the use of induction intravesical therapy in low-risk NMIBC but for intermediate-risk patients does recommend consideration of either 6 weeks of induction intravesical chemotherapy (with maintenance for an unspecified duration) or BCG (with 1 year of maintenance therapy). High-risk patients with CIS, HG T1 or high-risk Ta NMIBC should be offered 6 weeks of BCG followed by maintenance BCG for 3 years. The EAU recommends induction and 1 year of maintenance intravesical chemotherapy or BCG as options for intermediate-risk NMIBC, and induction plus 1-3 years of maintenance BCG for high-risk patients. The NCCN guidelines are less specific, with options including observation, intravesical mitomycin C or BCG, based on pathology. In patients responding to induction BCG, the NCCN recommends maintenance BCG with no defined schedule, although most NCCN members follow the SWOG protocol [63] .
Management of Recurrence after Intravesical BCG
The EAU offers definitions of BCG failure, which include progression to muscle-invasive disease, HG recurrence after completion of BCG maintenance and BCG-refractory disease, which includes HG Ta/T1 present at 3 months, Tis present at both 3 and 6 months, and HG tumour appearance during BCG therapy [64] [65] [66] . All these BCG failures are recommended to have early RC as a preferred option [67] , while non-HG/G3 recurrence after BCG for primary intermediate-risk tumours are recommended to [68, 69] , as an alternative to RC, but RC is the main option for these patients, as it is for persistent or recurrent T1 disease.
Indication for Radical Cystectomy
While NMIBC is usually managed with bladder preservation in mind, a number of instances should prompt early RC, as 'delayed cystectomy' has been suggested to have worse cancer-specific survival [70] and a number of clinical scenarios have been shown to be associated with compromised outcomes with continued attempts at intravesical management [19, 40, 71] .
The AUA recommends offering initial RC in patients with variant histologies, T1 tumours associated with CIS or lymphovascular invasion (LVI), and in high-risk patients with persistent HG T1 disease on repeat resection. Additionally, high-risk patients with persistent or recurrent disease within 1 year after two induction cycles of BCG or BCG plus maintenance should be offered RC. The EAU recommends that initial RC should be considered in patients with the highest risk of progression, which they define as those with T1G3/HG associated with concurrent bladder CIS, multifocal, large or recurrent T1G3/GH, T1G3/HG with CIS in the PU, variant histologies and LVI. RC is also recommended for BCG unresponsive tumours. The NCCN suggests early RC may be preferred for patients with T1 tumours which are multifocal, associated with LVI, or recur after BCG. NICE recommends offering RC to patients with high-risk NMIBC, variant histologies, based on presence of CIS, PU involvement, bladder neck involvement, tumour multifocality, and in whom BCG induction fails either because of intolerance or persistent/ recurrent disease.
Conclusions
Despite some variations in guidelines for NMIBC, significant consensus exists in the majority of areas. All guidelines generally apply a risk-stratified approach to sub-classifying NMIBC (Table 3) , and this stratification informs subsequent management including surveillance (Table 4) and intravesical therapy protocols (Table 5 ). In areas of unanimity, these recommendations are based on high-quality evidence or expert opinions that should provide guidance to patient management. In areas of discrepancy, physicians should take into account individual patient characteristics and adopt the most reasonable management strategy for the particular clinical scenario.
Key Points
• Properly performed and complete initial TUR of all visible bladder tumour is essential, and an early repeat resection should be performed when indicated.
• Patients should be risk stratified according to pathology, clinical history and response to intravesical therapy.
• According to risk stratification, patients should be offered expectant management, intravesical therapy or RC, as appropriate.
• The follow-up of NMIBC is based on the principle of regular cystoscopic surveillance because of risk of recurrence and progression.
• Non-invasive tests (i.e. urinary biomarkers, imaging)
should not replace cystoscopy in the surveillance of NMIBC.
